Sionna Therapeutics, Inc.
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$75.3M
- Total assets
- $326.0M
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $89.0M
- Operating income
- -$89.0M
- Income tax
- $0
- Net income
- -$75.3M
- EPS (basic)
- $-1.88
- EPS (diluted)
- $-1.88
Balance sheet
- Total assets
- $326.0M
- Current assets
- $241.4M
- Total liabilities
- $19.1M
- Current liabilities
- $11.7M
- Shareholders’ equity
- $306.8M
Cash flow
- Operating cash flow
- -$66.3M
- Investing cash flow
- -$118.7M
- Financing cash flow
- $205.7M
- Net cash flow
- $20.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-1.88
- Shares outstanding
- 47.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 7, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $75.3M.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sionna Therapeutics, Inc..
Write a review
News about Sionna Therapeutics, Inc.
News & sentiment via Polygon.io
